Program by Day

« Back

Print this page

	Personalized Program The Personalized Program enables you to compile an individual program with events and contributions of your interest. Therefore, it can be used very well to plan your actual congress visit at an early point of time. Please log in to use the Personalized Program.	» Login » Identification » Help

« previous day	Wednesday, 1. July 2009	next day »

No.	S-60 - Symposium
Time:	08.00-09.30
Room:	Blue Amphitheatre
Topic:	Anxiety
Track:	2 Clinical
Session title:	Disaster follow-up: International perspectives
	Joseph Zohar, Israel	Chair
	Manickam Thirunavukarasu, India	Co-Chair

001	9/11 – American insights
	Rachel Yehuda, USA	Speaker
002	1999 earthquake in Turkey – the lessons from a seven year follow-up
	Oguz Karamustafalioglu, Turkey	Speaker
003	Tsunami 2004 - retrospective introspection
	Manickam Thirunavukarasu, India	Speaker
004	Can PTSD be prevented?
	Joseph Zohar, Israel	Speaker

No.	S-61 - Symposium
Time:	08.00-09.30
Room:	Salle Maillot
Topic:	Genetics
Track:	1 Basic
Session title:	The genetics of unipolar depression and bipolar affective disorder
	Alexandra Schosser, United Kingdom	Chair
	Peter McGuffin, United Kingdom	Co-Chair

001	The uses and abuses of genome wide linkage and association studies
	Peter McGuffin, United Kingdom	Speaker
002	Genome-wide association studies of bipolar disorder
	Nick Craddock, United Kingdom	Speaker
003	Genetics of bipolar affective disorder
	Markus M. Nöthen, Germany	Speaker
004	A genome wide association study of unipolar depression
	Sarah Cohen-Woods, United Kingdom	Speaker

No.	S-62 - Symposium
Time:	08.00-09.30
Room:	Room 352AB
Topic:	Neurodegenerative Disorders
Track:	2 Clinical
Session title:	Lithium, neuroprotection and dementia
	Wagner F. Gattaz, Brazil	Chair
	Husseini Manji, USA	Co-Chair

001	Neuroprotective effects of lithium: in vitro and in vivo models
	Husseini Manji, USA	Speaker
002	Does lithium protect against dementia? Evidence from clinical and genetic studies.
	Wagner F. Gattaz, Brazil	Speaker
003	Epidemiological evidence on the effects of lithium on the prevalence of dementia
	Lars Vedel Kessing, Denmark	Speaker
004	Lithium for the treatment of mild cognitive impairment: Preliminary results of a double-blind, placebo controlled trial
	Orestes V. Forlenza, Brazil	Speaker

No.	S-63 - Symposium
Time:	08.00-09.30
Room:	Room 252B
Topic:	Affective Disorders (Bipolar)
Track:	2 Clinical
Session title:	How far are we from reducing suicide in bipolar disorder?
	Frank Bellivier, France	Chair
	Eduard Vieta, Spain	Co-Chair

001	Suicidal risk in BP patients and bipolar risk in suicidal patients?
	Philippe Courtet, France	Speaker
002	Gene-environment interaction and the risk of suicidal behavior in bipolar patients
	Bruno Etain, France	Speaker
003	Psychosocial interventions in bipolar disorder: Impact on morbidity and mortality
	Francesc Colum, Spain	Speaker
004	Suicide prevention in bipolar patients
	Guy Goodwin, United Kingdom	Speaker

No.	S-64 - Symposium
Time:	08.00-09.30
Room:	Room 241
Topic:	Addictive Disorders
Track:	1 Basic
Session title:	Brain imaging in addiction
	David A. Gorelick, USA	Chair
	Aviv Weinstein, Israel	Co-Chair

001	Role of dopamine in human drug self-administration
	Marco Leyton, Canada	Speaker
002	Role of brain mu-opioid receptors in cocaine addiction
	David A. Gorelick, USA	Speaker
003	Brain serotonin function in MDMA (ecstasy) users
	Franz Vollenweider, Switzerland	Speaker
004	Brain imaging studies of cognitive effects of recreational drugs
	Aviv Weinstein, Israel	Speaker

No.	S-65 - Symposium
Time:	08.00-09.30
Room:	Room 251
Topic:	Psychotic Disorders
Track:	3 Interface
Session title:	Functional psychopathology: Linking neurobiology with psychopathology
	Wolfgang Gaebel, Germany	Chair
	Veronica Larach-Walters, Chile	Co-Chair

001	Philosophical foundations of the relation between neurobiology and psychopathology
	Michael Musalek, Austria	Speaker
002	An introduction to functional psychopathology
	Wolfgang Gaebel, Germany	Speaker
003	Modules of the brain: Linking brain function to psychopathology
	Jürgen Zielasek, Germany	Speaker
004	Treatment of social cognition impairments in schizophrenia regarding facial affect recognition
	Veronica Larach-Walters, Chile	Speaker

No.	FC-23 - Free Communications
Time:	08.00-09.30
Room:	Room 351
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders VI
	Michel Dierick, Belgium	Chair
	Margareta Reis, Sweden	Co-Chair

001	Outcome in first-episode schizophrenia: 4-year follow-up
	Eva Ceskova, Czech Republic	Speaker
002	New diagnostic and treatment approaches to schizophrenia with obsessive-compulsive symptoms
	Ilya Reznik, Israel	Speaker
003	Visual scanning of natural scenes in schizophrenia: Effect of a task-driven exploration and scene semantic consistency
	Emmanuelle Boloix, France	Speaker
005	Heritability aspects of endocannabinoid functioning in schizophrenia
	Dagmar Köthe, Germany	Speaker

No.	FC-24 - Free Communications
Time:	08.00-09.30
Room:	Room 242A
Topic:	Neuroimaging
Session title:	Neuroimaging II
	Thomas Schlaepfer, Germany	Chair
	Jacques Bouchez, France	Co-Chair

001	Microstructural alterations of an orbital and medial prefrontal network in detoxified alcoholics as detected by voxel-based Diffusion Tensor Imaging
	Thomas Peschel, Germany	Speaker
002	Associations between gray matter abnormalities and cognitive function in the at-risk mental state
	Stefan Borgwardt, Switzerland	Speaker
003	Metabotropic Glutamat receptor 5 Imagingin major depressive disorder
	Alexandra Deschwanden, Switzerland	Speaker
004	Depressive symptoms and risk of white matter lesions. The SMART-MR study
	Anne Grool, Netherlands	Speaker
005	Resting state functional MRI and MR-spectroscopy in major depressive disorder: Preliminary results
	Dorothea Irene Horn, Germany	Speaker
006	An fMRI study investigating hippocampal volume, psychological stress and vulnerability for depression
	Katarina Dedovic, Canada	Speaker

No.	FC-25 - Free Communications
Time:	08.00-09.30
Room:	Room 242B
Topic:	Psychopharmacology
Session title:	Psychopharmacology III
	Stuart Montgomery, United Kingdom	Chair
	Monte Buchsbaum, USA	Co-Chair
	Daniel J. Mueller, Canada	Co-Chair

001	Impact of depression, anxiety comorbidity and antidepressant treatment on heart rate variability: A meta-analysis
	Daniel Quintana, Australia	Speaker
002	Social isolation alters the behavior effect of carbamazepine
	Noppamars Wongwitdecha, Thailand	Speaker
003	Effects of antipsychotics and vitamin C on the formation of reactive oxygen species
	Philip Heiser, Germany	Speaker
004	Chronic SSRI treatment in female rats: Dissociation of antidepressant action from hippocampal BDNF expression
	Anita C. Hansson, Germany	Speaker
006	The efficacy of eicosapentaenoic acid for major depression: Results of the OMEGA-3D trial
	Francois Lesperance, Canada	Speaker

No.	PL-04 - Plenary Lecture
Time:	09.45-10.30
Room:	Main Amphitheatre
Topic:	Other
Session title:	Emotion, decision making and psychopathology
	Norio Ozaki, Japan	Chair

001	Emotion, decision making and psychopathology
	Ray Dolan, United Kingdom	Speaker

No.	YS-04 - Young Scientists Award Session
Time:	09.45-10.30
Room:	Room 242A
Topic:	Other
Session title:	Other
	Celso Arango, Spain	Chair
	Martin Brüne, Germany	Co-Chair

001	Affective symptoms and body mass index (BMI): A life course approach
	Darya Gaysina, United Kingdom	Speaker
002	Mental disorders and suicidal ideation in primary care patients
	Jurate Peceliuniene, Lithuania	Speaker
003	Emotional interference in obsessive-compulsive disorder: A neuropsychological study using optimized emotional stroop test
	Naren Rao, India	Speaker
004	Deficits in implicit but not explicit reversal learning indexed by novel tasks in patients with obsessive-compulsive disorder
	Natalia Lawrence, United Kingdom	Speaker

No.	TG-07 - WFSBP Treatment Guidelines
Time:	11.00-12.30
Room:	Room 242A
Topic:	Other
Session title:	Eating disorders
	Michel Dierick, Belgium	Chair

	Martin Aigner, Austria	Presenter
	Roland Dardennes, France	Presenter

No.	D-07 - Debate
Time:	11.00-12.30
Room:	Room 351
Topic:	Childhood Adolescent Disorder
Session title:	Psychotropics in child psychiatry?
	Manuel Bouvard, France	Chair

	Celso Arango, Spain	Opponent
	David Coghill, United Kingdom	Proponent

No.	W-09 - Workshop
Time:	11.00-12.30
Room:	Room 251
Topic:	Genetics
Session title:	Molecular genetics of adult ADHD
	Andreas Reif, Germany	Chair

001	Genetic studies in IMPACT, the international multi-centre persistent ADHD collaboration
	Barbara Franke, Netherlands	Speaker
002	Functional studies of candidate genes involved in adult ADHD
	Jan Haavik, Norway	Speaker

No.	W-10 - Workshop
Time:	11.00-12.30
Room:	Room 242B
Topic:	Psychotic Disorders
Session title:	New tools for cognitive remediation in schizophrenia
	Nicolas Franck, France	Chair

001	Symptom oriented cognitive remediation in RECOS
	Pascal Vianin, Switzerland	Speaker
002	Cognition rehabilitation in schizophrenia: Costs and effectiveness
	Caroline Cellard, United Kingdom	Speaker

No.	S-66 - Symposium
Time:	11.00-12.30
Room:	Blue Amphitheatre
Topic:	Neuroimaging
Track:	1 Basic
Session title:	More insight into auditory verbal hallucinations
	Andre Aleman, Netherlands	Chair
	Iris Sommer, Netherlands	Co-Chair

001	Auditory hallucinations and perceptual mechanisms
	Peter Woodruff, United Kingdom	Speaker
002	Cerebral activity before and during auditory verbal hallucinations
	Iris Sommer, Netherlands	Speaker
003	Self-monitoring and inner speech models of AVH; Is there any evidence?
	Paul Allen, United Kingdom	Speaker
004	Right temporoparietal junction and spatial
	Marion Plaze, France	Speaker

No.	S-67 - Symposium
Time:	11.00-12.30
Room:	Salle Maillot
Topic:	Neuroimaging
Track:	1 Basic
Session title:	Neuroimaging the impulsivity in psychiatry
	Pascale Mazzola-Pomietto, France	Chair
	Eric Hollander, USA	Co-Chair

001	Ventral striatum and impulsivity: fMRI in pathological gambling, OCD, and autism
	Eric Hollander, USA	Speaker
002	Functional neural correlates of inhibitory control in mania and schizophrenia
	Arthur Kaladjian, France	Speaker
003	Genetic and disease related impact on the neural correlates of response inhibition in bipolar disorder
	Sophia Frangou, United Kingdom	Speaker
004	Functional correlates of cognitive control in children with attention-deficit hyperactivity disorder and their unaffected siblings
	Martijn Mulder, Netherlands	Speaker

No.	S-68 - Symposium
Time:	11.00-12.30
Room:	Room 352AB
Topic:	Anxiety
Track:	1 Basic
Session title:	The cortical-striatal network in obsessive-compulsive disorder and depression
	Martijn Figee, Netherlands	Chair
	Donald Malone, USA	Co-Chair

001	Limbic-prefrontal control is improved in paroxetine responders, but the ventral striatum is also involved in SSRI-response
	H.G. Ruhe, Netherlands	Speaker
002	The effects of ventral capsule/ventral striatum stimulation in depression
	Donald Malone, USA	Speaker
003	Imaging neurotransmission in the cortical-striatal network of OCD
	Martijn Figee, Netherlands	Speaker
004	Disinhibition of frontal-striatal circuits in the compulsive-impulsive spectrum
	Odile A. van den Heuvel, Netherlands	Speaker

No.	S-69 - Symposium
Time:	11.00-12.30
Room:	Room 252B
Topic:	Psychopharmacology
Track:	1 Basic
Session title:	Promises and pitfalls of genetic research in drug treatment of depression and schizophrenia
	Daniel J. Mueller, Canada	Chair
	James L. Kennedy, Canada	Co-Chair

001	Results from a whole genome association study in depression: Will putative etiologic genes predict antidepressant response?
	Pierandrea Muglia, United Kingdom	Speaker
002	Impact of MAOA-, COMT- and serotonergic system gene variants in antidepressant drug treatment
	Katharina Domschke, Germany	Speaker
003	Pharmacogenetics of antidepressants in mood disorders, what can be improved? A proposal for methodological guidelines
	Alessandro Serretti, Italy	Speaker
004	Pharmacogenetics of antipsychotics using an animal model
	Dan Rujescu, Germany	Speaker

No.	S-70 - Symposium
Time:	11.00-12.30
Room:	Room 241
Topic:	Brain Function
Track:	1 Basic
Session title:	Glia cell pathology in psychiatric disorders
	Matthias Rothermundt, Germany	Chair
	Damir Janigro, USA	Co-Chair

001	Glial changes in post mortem brains of individuals with psychiatric disorders
	Johann Steiner, Germany	Speaker
002	Astroglial antioxidant defense alteration in bipolar disorder
	Carlos Alberto Goncalves, Brazil	Speaker
003	Inflammatory markers in children and adolescents with psychotic disorders, the role of glia cells
	Tatiana Falcone, USA	Speaker
004	Glial activation in psychiatric disorders
	Matthias Rothermundt, Germany	Speaker

No.	FC-26 - Free Communications
Time:	12.30-14.00
Room:	Room 351
Topic:	Affective Disorders (Unipolar)
Session title:	Affective Disorders (Unipolar) III
	Philippe Fossati, France	Chair
	Alexandre Dailliet, Belgium	Co-Chair

001	Higher psychological pain during a major depressive episode may be a factor of vulnerability to suicidal ideation and act
	Emilie Olié, France	Speaker
002	Association between IL-12 secretion levels in major depressive disorder and symptoms severity, before and after mitogen stimulation
	Platon Christopoulos, Greece	Speaker
003	Localization of white matter lesions and effect of vascular risk factors in late-onset major depression
	Rikke Dalby, Denmark	Speaker
004	Cognitive effects of electroconvulsive therapy in depression: A meta-analysis
	Maria Semkovska, Ireland	Speaker
005	Early separations as risk factor for later depressive, panic, generalized anxious and paranoid disorder
	Dusan Lazarevic, Serbia and Montenegro	Speaker
006	Neurobiological bases of suicidality in major depression
	Martin Desseilles, Belgium	Speaker

No.	FC-27 - Free Communications
Time:	12.30-14.00
Room:	Room 242A
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders VII
	René Kahn, Netherlands	Chair
	Wolfgang Gaebel, Germany	Co-Chair

001	Some oxidative stress markers in schizophrenic patients with and without history of suicidal behavior
	Doina Cozman, Romania	Speaker
002	Theta Burst stimulation in schizophrenia
	Jerome Brunelin, France	Speaker
003	Oscillatory brain dynamics reflected in the frontal auditory evoked potentials in healthy subjects and schizophrenic patients
	Josef Zislin, Israel	Speaker
004	Obsessive-compulsive symptom dimensions in schizophrenia patients with obsessive-compulsive disorder
	Michael Poyurovsky, Israel	Speaker
005	Fast face recognition in schizophrenia and spatial frequency processing
	Vincent Laprévote, France	Speaker
006	Coherent analysis and clinical correlates in patients with first episode of schizophrenia and schizoaffective disorder
	Yuliya Zaytseva, Russia	Speaker

No.	FC-28 - Free Communications
Time:	12.30-14.00
Room:	Room 242B
Topic:	Psychopharmacology
Session title:	Psychopharmacology IV
	Larry Siever, USA	Chair
	Alessandro Serretti, Italy	Co-Chair

001	The effect of Ketamine on sensorimotor gating - comparison of human and animal data
	Tomas Palenicek, Czech Republic	Speaker
002	Treatment resistant catatonia responding to zolpidem: Case reports and literature review
	Cristinel Coconcea, USA	Speaker
003	Rapid metabolism of antipsychotics and akathisia in schizophrenic Court-Order detention patients: A selection bias
	Carel de Blécourt, Netherlands	Speaker
004	Acute Stress Responsiveness of BDNF in the rat prefrontal cortex is modulated by antidepressants
	Therese M. Jay, France	Speaker
005	Dexamphetamine effects on prepulse inhibition of the startle reflex in healthy volunteers
	Mathew Martin-Iverson, Australia	Speaker
006	Efficacy of amantadine in the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study
	Sofia Pappa, United Kingdom	Speaker

No.	P-32 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Addictive Disorders
Session title:	Addictive Disorders III
	Aviv Weinstein, Israel	Chair

001	Pain, personality and addiction: Pain coping strategies related to personality traits in substance abusers
	Alireza Homayouni, Iran	Presenter
002	Personality and tendency to addiction: Comparison between addicts and nonaddicts
	Alireza Homayouni, Iran	Presenter
003	Family burden in alcohol dependence
	Elias Tzavellas, Greece	Presenter
004	Tiagabine in the management of collateral psychopathology during alcohol detoxification
	Elias Tzavellas, Greece	Presenter
005	Personality of polysubstance abusers with the acute psychotic episode
	Milan Zdravkovic, Serbia and Montenegro	Presenter
006	Apoptosis of immune competent cells in alcoholic patients
	Nikolay Bokhan, Russia	Presenter
007	Alcoholism, comunication and family
	Paula Santos, Portugal	Presenter
008	Correlates of lifetime alcohol misuse among older community residents in Brazil
	Sergio Blay, Brazil	Presenter
009	The influence of alcohol metabolizng enzymes and their combinations on drinking behaviors of Korean young adults
	Sie-Kyeong Kim, Korea, Republic of	Presenter
010	Serotonin 5-HT2B receptors are required for MDMA-induced hyperlocomotion, locomotor sensitization, CPP and serotonin release in vivo
	Stephane Doly, France	Presenter
011	Steroid hormones and aggression in alcohol dependent patients in the conditions of social isolation
	Svetlana Ivanova, Russia	Presenter
012	Trazadone in the treatment of insomnia in patients on methadone maintenance
	Milica Nikic, Serbia and Montenegro	Presenter
013	Alcohol modulates the properties of benzodiazepine receptors peripheral type
	Tamara Shushpanova, Russia	Presenter
015	Low self-esteem as a risk factor for alcohol abuse in undergraduate students
	Veronica Ituarte, Mexico	Presenter
016	Variability of the human MPDZ gene sequence and association with alcoholism
	Victor Karpyak, USA	Presenter
017	Paroxetine compared to Alprazolam in the treatment of alcohol dependence
	Vilma Lazarova, Macedonia, The former Yugoslav	Presenter
018	Dopamine partial agonist effect on the craving for smoking in patients with schizophrenia
	Young-Sik Lee, Korea, Republic of	Presenter
019	Psychiatric comorbidity of internet addiction in Romanian teenagers: An observational study
	Cristinel Stefanescu, Romania	Presenter

No.	P-33 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Affective Disorders (Unipolar)
Session title:	Affective Disorders (Unipolar) III
	E. Mohandas, India	Chair

001	Preeclampsia in pregnant women depression
	Aida Ansari, Iran	Presenter
002	Depression post myocardial infarction: A cross sectional study in University Malaya Medical Center
	Amer Siddiq Amer Nordin, Malaysia	Presenter
003	Associations between cyclothymic temperament and bipolarity factors in recurrent depressive patients
	Anwar Mechri, Tunisia	Presenter
004	Cognitive inhibition and working memory in unipolar depression
	Benedicte Gohier, France	Presenter
006	Disfunctional cognitive schemes in depressed patients
	Iosif Gabos Grecu, Romania	Presenter
007	Outcome prediction of the Hamilton depression rating scale (HAM-D 17 item) in patients with moderate depression - an artificial neural network (ANN) approach combined with wavelet decomposition
	Jürgen Müller, Germany	Presenter
008	High - dose St. John´s wort extract STW 3 - VI is a safe and effective treatment option in mild depression - results of a revaluation
	Jürgen Müller, Germany	Presenter
009	Investigating models of affect: Comparison of regional brain asymmetry in MDD and PTSD
	Kristi Griffiths, Australia	Presenter
010	VEGF serum levels in depressed patients during SSRI antidepressant treatment
	Luisella Bocchio-Chiavetto, Italy	Presenter
011	Cardiovascular disorders in comorbidity with depression
	Marija Burgic-Radmanovic, Bosnia and Herzegovina	Presenter
012	Extended release quetiapine fumarate (quetiapine XR) monotherapy for the treatment of patients with major depressive disorder (MDD): A randomised, placebo-controlled clinical trial
	Nizar El-Khalili, USA	Presenter
013	Late-life depression: Differences between early and late onset illness in a melancholic hospitalized sample
	Pilar Alvarez, Spain	Presenter
014	Platelet serotonergic binding sites in melancholic depression with and without psychotic features: Relationship with clinical and follow-up variables
	Pilar Alvarez, Spain	Presenter
015	Circular depressions and factor of seasonality
	Sergejus Andruskevicius, Lithuania	Presenter
016	Brain lipid peroxidation enzymes, stress and stress - induced anhedonia in CD1 mice
	Tatyana Strekalova, Netherlands	Presenter
017	Associations between depression and cardiovascular disease in patients with late onset single episode major depressive disorder
	Torben Albert Devantier, Denmark	Presenter
018	Subclinical hypothyroidism predicts treatment outcome of inpatients with major depressive disorder
	Toshimi Owashi, Japan	Presenter
019	Homeopathy versus fluoxetine for moderate to severe depression: Double-blind, randomized non-inferiority trial
	Ubiratan Adler, Brazil	Presenter
020	Amygdala volumes in a sample of current depressed and remitted depressed patients and healthy controls
	Valentina Lorenzetti, Australia	Presenter

No.	P-34 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Anxiety
Session title:	Anxiety III
	Mathias Berger, Germany	Chair

001	Ex-service men and psychotraumatism in Algeria
	Benabbas Malik, Algeria	Presenter
002	Combination of pharmacotherapy and psychotherapy in the treatment of patients with panic disorder
	Dusan Kolar, Serbia and Montenegro	Presenter
003	HPA-axis behavior is correlated with personality
	Danka Savic, Serbia and Montenegro	Presenter
004	Predictors of clinical response to placebo in patients with anciety disorder
	Roxana Galeno, Argentina	Presenter
005	Cannabinoid receptor ligands suppress anxiety-related effects of d-amphetamine and nicotine in the elevated plus maze test in mice
	Grazyna Biala, Poland	Presenter
006	Parental anxiety and quality of life in children with blindness in Ababasire institution
	Homayoon Naji, Iran	Presenter
007	Relationship between Hepatocyte growth factor and anxiety and depression
	Jotaro Akiyoshi, Japan	Presenter
008	The reletionship between depersonalization, derealization and number of traumatic events during childhood and adolescence in healthy individuals
	Katarina Adamcova, Czech Republic	Presenter
009	Mental fatigue after brain injury and the supporting systems of the brain
	Lars Rönnbäck, Sweden	Presenter
010	Anxiolytic efficacy and time to onset of pregabalin in patients with Generalized Anxiety Disorder: Open label, non-comparative, flexible-dose study
	Matthias Brasser, Germany	Presenter
011	Pregabalin treatment for Generalized Anxiety Disorder under clinical practice conditions: Global response as assessed by patients and physicians
	Matthias Brasser, Germany	Presenter
012	Efficacy of ECT in chronic, severe, antidepressant - and CBT refractory posttraumatic stress disorder: An open, prospective study
	Mushtaq Margoob, India	Presenter
013	Cognitive mechanisms involved in PTSD and its treatment
	Myriam El-Khoury, France	Presenter
014	Differential rearing condition interferes with caffeine’s effect in the adult rats
	Noppamars Wongwitdecha, Thailand	Presenter
015	Effect of barakol on the elevated plus-maze behavior of social and isolation reared rats
	Noppamars Wongwitdecha, Thailand	Presenter
016	Stress during brain development reduces the anti-aggressive effect of clonidine
	Noppamars Wongwitdecha, Thailand	Presenter
017	Diagnostics and rehabilitation of patients with posttraumatic stressful frustration
	Oleg Panchenko, Ukraine	Presenter
018	Syndrome of medical posttraumatic stressful dezoder at children of preschool and early school age
	Oleg Panchenko, Ukraine	Presenter
019	Parity of biological and psychological age in psychiatric practice
	Oleg Panchenko, Ukraine	Presenter
020	Posttraumatic Stress Disorder: predictors factors
	Policarpo Rebolledo, Chile	Presenter

No.	P-35 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders VI
	Mohammed Shahid, United Kingdom	Chair

001	Corpus callosum abnormalities in schizophrenia: Potential association to symptom cerebral substrate and age course of illness
	Giuseppe Bersani, Italy	Presenter
002	Factors associated with weight change in a 16-week randomized double-blind, double-dummy trial of sublingual orally disintegrating olanzapine vs. oral olanzapine in patients who gained weight during olanzapine treatment: The PLATYPUS Study
	Jamie Karagianis, Canada	Presenter
003	Disturbed prepulse inhibition in patients with schizophrenia is consequential to selective attention deficits
	Kirsty Scholes, Australia	Presenter
004	Subjective experience with an antipsychotic treatment
	Ludvik Nabelek, Slovak Republic	Presenter
005	Prepulse inhibition as a biological marker of at risk mental state of schizophrenia
	Masatoshi Okumura, Japan	Presenter
006	Discriminant analysis in schizophrenia and healthy controls using preforntal activation during forntal lobe tasks: A near-infrared spectroscopy study
	Michiyo Azechi, Japan	Presenter
007	Mismatch negativity in schizophrenia and patients at risk
	Mitja Bodatsch, Germany	Presenter
008	Hepatitis B in schizophrenia: Prevalence and comparison with healthy controls
	Mouna Ayachi, Tunisia	Presenter
009	Cariprazine (RGH-188), a potential antipsychotic with Dopamine D3/D2 functional antagonist properties, attenuates manic-like behaviors in animal models
	Nika Adham, USA	Presenter
011	Rational for the use of neurofeedback as a rehabilitation tool to overcome neurocognitive impairments in schizophrenia
	Nuno Rocha, Portugal	Presenter
012	Neurocognitive predictors of proactive coping in schizophrenia
	Nuno Rocha, Portugal	Presenter
013	A new tool to evaluate anxiety in schizophrenia : Anxiety Scale in Schizophrenia (ASS)
	Pierre-Marie Llorca, France	Presenter
014	Spectral karyotyping of schizophrenia populations in Tamilnadu, South India
	Pappuswamy Manikantan, India	Presenter
015	Cognitive antismoking and psychiatric effects of Varenicline in patients with schizophrenia or schizoaffective disorder
	Robert C. Smith, USA	Presenter
016	Schizophrenics show an upregulation of DNA-methyltransferase 1 (DNMT1)in blood lymphocytes: Implications for the epigenitic methylation hypothesis of schizophrenia
	Robert C. Smith, USA	Presenter
017	Treatment of schizophrenia with long-acting injectable risperidone
	Sanja Stanojkovic, Serbia and Montenegro	Presenter
018	Glutamate and BDNF levels in psychosis
	Sonia Ruiz de Azua, Spain	Presenter
019	Association of Psychopathology and Deficits in Facial Affect Recognition in Bimodal Context in Greek patients with schizophrenia
	Vassiliki Psarra, Greece	Presenter
020	Recurrence pattern of the patients who had been diagnosed with brief psychotic disorder: 2 years of follow up by retrospective chart review
	Won-Myong Bahk, Korea, Republic of	Presenter

No.	P-36 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Genetics
Session title:	Genetics III
	Peter McGuffin, United Kingdom	Chair

001	Serotonin transporter promoter gene polymorphism and response to antidepressant treatment
	Eduardo Cesar Rodriguez Garin, Argentina	Presenter
002	Electroconvulsive seizures regulate gene expression of neurotrophic, angiogenic and antidepressive signaling pathways
	Elida Ojopi, Brazil	Presenter
003	The impact of CYP2D6 and CYP2C19 on antidepressant therapy for major depression
	Elida Ojopi, Brazil	Presenter
004	The C (-1019) G serotonin 1A polymorphism is associated with comorbid anxiety and depression
	Esther Molina, Spain	Presenter
005	Variation at the 5-HT2A receptor gene is associated to panic syndrome
	Esther Molina, Spain	Presenter
006	Analysis of dopamine receptor D4 gene and serotonin receptor 2C gene polymorphisms in patients with alcoholism and opioid addiction from Russia
	Gulnaz Faskhutdinova, Russia	Presenter
007	Gene expression profiles in human peripheral blood mononuclear cells induced by sleep deprivation
	Jong-Woo Kim, Korea, Republic of	Presenter
008	Neuropeptide Y and schizophrenia : Genetic association study in Korean population
	Joo-Ho Chung, Korea, Republic of	Presenter
009	Relations between 5-HTTLPR polymorphism, aggression, impulsivity and neuroticism in a Chilean borderline personality disorder sample (Proyecto FONDECYT 1071045).
	Juana Villarroel, Chile	Presenter
010	A Microarray analysis of gene expression following Lithium-induced Euthymia in Bipolar disorder type 1 patients and resultant synaptic plasticity
	Lana Kirkby, South Africa	Presenter
011	RGS4 in pathophysiology of schizophrenia
	Monika Vrajova, Czech Republic	Presenter
012	The role of recent adaptative selection on schizophrenia susceptibility genes
	Noa Carrera, Spain	Presenter
013	Study of association between tryptophan hydroxylase-2 and depression of late - onset
	Patricia Pereira, Brazil	Presenter
014	Polymorphisms in GRM3 and HOMER1 genes and their possible role for early treatment response in schizophrenia
	Rebecca Schennach-Wolff, Germany	Presenter
015	Association between D2 Dopamine Receptor (DRD2) Gene Polymorphism and Posttraumatic Stress Disorder in Vietnam War Veterans of Korea
	Tae-Yong Kim, Korea, Republic of	Presenter
016	The role of 677C>T genetic polimorphism of the methylenetetrahydrofolate reductase gene in schizophrenia
	Vasile Chirita, Romania	Presenter
017	The MAO-A gene, adverse life events and adult ADHD
	Wiplove Lamba, Canada	Presenter
018	A family study of the association of the dopamine gene polymorphisms with temperament and behavioral problems
	Wojciech Dragan, Poland	Presenter
019	Specific gene expression in the periaqueductal grey predicts a rats preference for a proactive, reactive or shifting emotional coping style
	Zoe Brett, Australia	Presenter
020	Association between Thrombospondin 1 (THBS1) gene polymorphisms and schizophrenia in Korean population
	Dong-Kee Hwang, Korea, Republic of	Presenter

No.	P-37 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Neuroimaging
Session title:	Neuroimaging II
	Rupert Lanzenberger, Austria	Chair

001	The functional neuroanatomy of working memory in very preterm born young adults following neonatal brain injury
	Anastasia Kalpakidou, United Kingdom	Presenter
002	Subjective loudness of auditory-verbal hallucinations interferes with processing in brain areas implicated in inner speech
	Ans Vercammen, Netherlands	Presenter
003	Brain [18F]MPPF imaging in eating disorders suggests specific serotoninergic organic background
	Bogdan Galusca, France	Presenter
004	Neural mechanisms of empathy in boys with autism spectrum disorder and their unaffected fathers
	Ellen Greimel, Germany	Presenter
005	Structural covariance in the hallucinating brain modulated by hallucination severity: A voxel-based morphometry study
	Gemma Modinos, Netherlands	Presenter
006	Relationship between glutamate levels and medial temporal function in the At Risk Mental State
	Isabel Valli, United Kingdom	Presenter
007	Fronto-limbic dysfunction in borderline personality disorder: A 18F-FDG Positron Emission Tomography study
	José Salavert Jiménez, Spain	Presenter
008	Individual differences in socio-affective skills influence the neural bases of anger processing
	Lydia Pouga, France	Presenter
009	FDG - PET changes in a patient with neurosyphilis
	Manu Mathews, USA	Presenter
010	Effect of catechol-O-methyltransferase val158met genotype on emotional intelligence and neural activation during emotional processing of words
	Marte Swart, Netherlands	Presenter
011	Imaging serotonin-1A receptor asymmetry in language areas using [carbonyl-11C]WAY-100635 and positron emission tomography
	Martin Fink, Austria	Presenter
012	Is hypometabolism in limbic and neocortical areas a specific feature of dementia? Results from a positron emission tomography study with cognitively normal elders
	Pedro Curiati, Brazil	Presenter
013	Emotional salience of visual scenes enhances repetition suppression in stimulus-related brain regions
	Sarah Zweynert, Germany	Presenter
014	Cerebral involvement in chronic hepatitis C virus infection assessed by magnetic resonance imaging
	Simon Hjerrild, Denmark	Presenter
015	Small amygdala-high aggression: On the role of the amygdala in modulating normal aggression in healthy subjects
	Swantje Matthies, Germany	Presenter
016	Pretreatment MR-scanning in OCD
	Tue Hartmann, Denmark	Presenter
017	A possible biological marker to differentiate between remitted bipolar I and bipolar II disorder using combined FDG-PET brain imaging and executive function assessment
	Tung-Ping Su, Taiwan	Presenter
018	Robust interaction of emotion and cognition in a working memory task with emotional stimuli
	Wolfgang Huf, Austria	Presenter
019	Association between triallelic polymorphism of the serotonin transporter and [18F]MPPF binding potential over 5-HT1A receptor in healthy subjects
	Philippe Gorwood, France	Presenter

No.	P-38 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychopharmacology
Session title:	Psychopharmacology II
	Brian E. Leonard, Ireland	Chair

001	Comparison of Olanzapine long-acting injection switching methods: An 8-month analysis of patients with schizophrenia at risk of relapse
	Elena Perrin, USA	Presenter
002	Long-term open-label safety of olanzapine long-acting injection: 190-week interim results
	Elena Perrin, USA	Presenter
003	Different art therapies applied with the antipsychotics
	Elizabeth Peli-Hasz, Hungary	Presenter
004	Eating disorders: Bibliotherapeutics to increase the pharmacotherapeutic compliance
	Elizabeth Peli-Hasz, Hungary	Presenter
005	Effect of alcoholic extract of hypericum perforatum on fear behavior in adult male rats
	Gholamhassan Vaezi, Iran	Presenter
006	Effect of inhalation alcoholic extract of Peganum harmala, on induction of anxiety like behavior in elevated plus-maze
	Gholamhassan Vaezi, Iran	Presenter
007	What pharmacological agents are most efficacious for the treatment of cognitive and behavioural problems following traumatic brain injury?
	Jane Mathias, Australia	Presenter
008	A randomized, placebo-controlled, double-blind, crossover study to investigate the residual effects of ramelteon (8 mg) and zopiclone (7.5 mg) on actual driving, memory, psychomotor performance and body balance in healthy volunteers
	Joris Verster, Netherlands	Presenter
009	Methylphenidate significantly improves declarative memory functioning in adult patients with Attention-Deficit Hyperactivity Disorder (ADHD)
	Joris Verster, Netherlands	Presenter
010	Can MDR 1 Polymorphism predict the side effect of oros-methylphenid in children and adolescents with Attention Deficit/ Hyperactivity Disorder?
	Ki-Hwan Yook, Korea, Republic of	Presenter
011	Prevalence of Metabolic Syndrome in chronic female patients
	Liliana Rendon, Paraguay	Presenter
012	Clinical interest of measuring out serical valproic acid rate in psychiatry
	Jean-Michel Pinoit, France	Presenter
013	Depressive syndromes and suicides of subjects treated with varenicline: Psychiatric and neurobiolological aspects
	Romain Padovani, France	Presenter
014	Atypical antipsychotics and social functioning in schizophrenic patients
	Marijo Vrdoljak, Croatia	Presenter
015	Maintaining of long-term effect of wellness program in psychiatric patients
	Sladjana Strkalj Ivezic, Croatia	Presenter
016	Reward sensitivity and response to the augmentation with topiramate in treatment-resistant anxiety
	Sorina Elena Nastase, Romania	Presenter
017	Topiramate in psychiatry as illustrated by an inpatient data base
	Sorina Elena Nastase, Romania	Presenter
018	The beneficial effect of Milnacipran on Fibromyalgia is not related to its antidepressant effects: A European, Multicenter, Controlled Trial
	Yves Mainguy, France	Presenter
019	The effect of Milnacipran on pain modulatory systems in Fibromyalgia: An FMRI analysis
	Richard Gracely, USA	Presenter
020	Control of Tourette’s syndrome with Paliperidone and Topiramate: A case report
	Ioanna Fotara, Greece	Presenter

No.	P-39 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychopharmacology
Session title:	Pschopharmacology/ Antipsychotics II
	Georg Juckel, Germany	Chair

001	Gabapentin is an important adjuvant in the treatment of resistant schizophrenia
	Caroline Demily, France	Presenter
002	Next-generation GRII antagonist prevents and reverses antipsychotic-induced weight gain
	Robert Roe, USA	Presenter
003	Mifepristone reduces weight gain associated with Risperidone use
	Robert Roe, USA	Presenter
004	Use of nicotine as augmentation agent in schizophrenia treatment
	Christos Tsopelas, Greece	Presenter
005	Atypical antipsychotics combination at medical discharge from psychiatry hospitalization unit
	Cristina Domenech Abella, Spain	Presenter
006	Treatment of severe hospitalized bipolar affective and schyzoaffective disorders in naturalistic conditions: Gender differencies
	Cristina Domenech Abella, Spain	Presenter
007	Prepulse inhibition of the startle response in amisulpride - treated patients: Comparison with typical antipsychotics
	Gabriel Rubio, Spain	Presenter
008	Expirience with zuclopenthixol on female forensic ward in specializad psychiatric hospital "gornja toponica"
	Jelena Mladenovic, Serbia and Montenegro	Presenter
009	Influence of clopixol monotherapy on improvement of quality of life in inpatient conditions on female forensic ward in specialized Psychiatric Hospital "gornja toponica"
	Jelena Mladenovic, Serbia and Montenegro	Presenter
010	Psychological stress and body temperature: Effects of Alprazolam and Flupentixol
	Juliane Hellhammer, Germany	Presenter
011	Haloperidol and atypical antipsychotics in the long-term treatment of psychotic disorders: Preliminary data from a naturalistic study
	Massimo Carlo Mauri, Italy	Presenter
012	Quetiapine and hypothyroidism: A literature review
	Vassilis Kontaxakis, Greece	Presenter
013	Spontaneous resolution of quetiapine induced hypothyroidism without quetiapine discontinuation
	Vassilis Kontaxakis, Greece	Presenter
014	Impact of haloperidol and Quetiapine on the expression of genes encoding antioxidant enzymes in human Neuroblastoma SH-SY5Y cells
	Philip Heiser, Germany	Presenter
015	Effect of perospirone on sLORETA images of P300 and social cognition in schizophrenia
	Tomiki Sumiyoshi, Japan	Presenter
016	Cognitive remediation therapy in schizophrenia: Experience of a 12-month follow up group
	Veronique Lambolez, France	Presenter
017	Use of aripiprazole and clozapine in the treatment of resistant schizophrenia: Two case reports
	Veronique Lambolez, France	Presenter
018	The A-effect of aripiprazole
	Xiaolei Yu Baran, USA	Presenter
019	Flexible doses of paliperidone ER in non-acute patients with schizophrenia switched due to lack of tolerability with their previous oral antipsychotic
	Dagmar Hoeben, Belgium	Presenter
020	A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with oral risperidone
	Dagmar Hoeben, Belgium	Presenter
021	Safety, tolerability and treatment response of flexible doses of Paliperidone ER in acutely exacerbated patients with schizophrenia
	Dagmar Hoeben, Belgium	Presenter

No.	P-40 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Other
Session title:	Other/ Pain/ Stress
	Victoria Valdez, Ecuador	Chair

001	Stress-phase orientated conception of stress-related and neurotic disorders
	Ada Tadevosyan, Armenia	Presenter
002	Psychiatric treatment in neuropathic pain
	Adela Ciobanu, Romania	Presenter
003	The effects of prenatal morphine exposure on pain response
	Aliakbar Alijarahi, Iran	Presenter
004	Is fibromyalgia an overlapping of rheumatic, immunological and psychiatric entities? A clinical setting work with 400 patients
	Andrea Lopez Mato, Argentina	Presenter
005	Relationship between neuroendocrine and immunological abnormalities in 20 chronic fatigue syndrome female patients
	Andrea Lopez Mato, Argentina	Presenter
006	Salivary cortisol responses of patients with migraine in a psychosocial stress test
	Anne-Katrin Puschmann, Germany	Presenter
007	Atypical facial pain
	Eda Guertzenstein, Brazil	Presenter
008	Does fibromyalgia syndrome exist?
	Eda Guertzenstein, Brazil	Presenter
009	The sensitization of the acoustic startle response persists for a long-term after chronic variable stress
	Keisuke Fujiwara, Japan	Presenter
010	Association of activity of antioxidative enzymes with level of thyroid hormones in patients with neurotic disorders
	Lyudmila Smirnova, Russia	Presenter
011	Effects of long-term increase of oxytocin levels on anxiety - like behavior and selected stress systems
	Maria Ondrejcakova, Slovak Republic	Presenter
012	Exhaustive screening of acute psychological stress-responsive cytokines in healthy university students
	Sakurako Katsuura, Japan	Presenter
013	Is Chronic Fatigue Syndrome a postviral disease? Quantification of antibodies and cytokines in Chronic Fatigue Syndrome
	Tomás Maresca, Argentina	Presenter
014	Relation between Chronic Fatigue Syndrome, Hypotalamus-Pituitary-Adrenal axis and lymphocytosis alterations in 20 female outpatients
	Tomás Maresca, Argentina	Presenter
015	Behaviour pattern, stress, and conformational properties of albumin binding sites in rats with experimental hemorrhage
	Varavara Kalinina, Russia	Presenter
016	Analgesic activity of bi - and polycyclic frame amines derivatives
	Helen Zlenko, Ukraine	Presenter
017	Basical emotions in a cohort of 300 fibromyalgic patients in the first consultation
	Tomás Maresca, Argentina	Presenter
018	Fibromyalgia and clinical presentation in 300 patients. How many years of misdiagnosis?
	Pablo Beretta, Argentina	Presenter
019	Relationship between chronic fatigue syndrome hypocortisolemia and indolamine and catecholamine alterations in 30 female patients
	Pablo Beretta, Argentina	Presenter
020	Treatment of fibromyalgia and related entities: Results in more than 300 patients
	Pablo Beretta, Argentina	Presenter
021	Traumatic stress and fibromyalgia. More than 300 cases
	Andrea Lopez Mato, Argentina	Presenter

No.	P-41 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Other
Session title:	Other/ Women's Health and Gender
	Angelika Wieck, United Kingdom	Chair

001	Psychiatric manifestations of antiphospholipid syndrome during pregnancy
	Iannis Zervas, Greece	Presenter
002	Character and temperament - sex or gender related?
	Dragana Duisin, Serbia and Montenegro	Presenter
003	The impact of maternal psychopathology on young females
	Feryal Cam Celikel, Turkey	Presenter
004	Menstrual parameters and serine 9 glicinepolymorphism in PMDD
	Gislene Cristina Valadares, Brazil	Presenter
005	Serine 9 glycine D3R polymorphism and appetite changes in PMDD women
	Gislene Cristina Valadares, Brazil	Presenter
006	Psychological reactions of woman with late pregnancy abortion
	Gordana Nikolic, Serbia and Montenegro	Presenter
007	Nonverbal fluency: Sex or gender characteristic
	Gordana Nikolic-Balkoski, Serbia and Montenegro	Presenter
008	Domestic violence against the Iranian pregnant women
	Hamidreza Behnam, Iran	Presenter
009	Sexual health in Parkinsons disease
	Jacinto Azevedo, Portugal	Presenter
010	The dexamethasone suppression test and its relationship to entrapment and mental defeat in women experiencing intimate partner violence
	Kaitlin Chivers-Wilson, Canada	Presenter
011	Anxiety and depression in pregnancy: Relationship with sleep quality
	Emiko Manabe, Japan	Presenter
012	Insomnia and sleep-awake rythem in pregnant women
	Kaori Matsuda, Japan	Presenter
013	Psychological experiences of family members about disable children
	Khosrow Tavakol, Iran	Presenter
014	Postpartum affective symptoms and its link to mother-infant bonding
	M. Luisa Imaz, Spain	Presenter
015	Compare the gender types of employed Iranian women regarding their mental health and marital satisfaction
	Mahnaz Aliakbari Dehkordi, Iran	Presenter
016	Comparison of sexual function and mental health between marriage well-adjusted and maladjusted women
	Shirin Kayghobadi, Iran	Presenter
017	Prevalence and treatment of mood symptoms in patients with late-onset delusional disorder
	Rebecca Anglin, Canada	Presenter
018	The Neuroimmunology of Neuroleptic Malignant Syndrome
	Rebecca Anglin, Canada	Presenter
019	Psychoneuroimmunology aspect of gynecological pathology
	Regina Nasyrova, Russia	Presenter
020	Work inability as psychic reaction to recurrent breast cancer - a clinical case
	Tomislav Peharda, Croatia	Presenter

No.	FC-29 - Free Communications
Time:	14.00-15.30
Room:	Room 242A
Topic:	Childhood Adolescent Disorder
Session title:	Childhood & Adolescent Disorders I
	Manuel Bouvard, France	Chair
	Johannes Thome, United Kingdom	Co-Chair

001	Transcranial brain sonography (TBS), task dependent motor performance and cortical motor excitability measured by transcranial magnetic stimulation (TMS) in children with Tic/Tourette syndrome and in ADHD children
	Johannes Buchmann, Germany	Speaker
002	Contribution of cognitive evaluation of states of awareness associated with memories to the understanding of the clinical features of Asperger's syndrome
	Laetitia Bon, France	Speaker
003	Neurofeedback for children with Attention Deficit/ Hyperactivity Disorder (ADHD): Clinical and neurophysiological results of a randomised controlled study
	Petra Studer, Germany	Speaker
004	QEEG investigation of school-age children with autism
	Natalia Gorbachevskaya, Russia	Speaker
005	Preschoolers with behavioral and emotional disorders show increased HPA-axis activity compared to healthy controls
	Martin Hatzinger, Switzerland	Speaker
006	Neurobiofeedback in pediatric bipolar disorder and Attention Deficit Hyperactivity Disorder: Is it differential diagnostic tool in child psychiatry?
	Miodrag Stankovic, Serbia and Montenegro	Speaker

No.	FC-30 - Free Communications
Time:	14.00-15.30
Room:	Room 242B
Topic:	Neuroimaging
Session title:	Neuroimaging III
	Bruno Millet, France	Chair
	Matthaeus Willeit, Austria	Co-Chair

001	Ventral striatal activation during reward anticipation correlates with impulsivity in alcoholics
	Jana Wrase, Germany	Speaker
002	Functional connectivity of right insula during self-face processing
	Rajamannar Ramasubbu, Canada	Speaker
003	Two days treatment of auditory hallucinations by high frequency rTMS guided by cerebral imaging: A 6 months follow-up study
	Aurelie Montagne-Larmurier, France	Speaker
004	Intention to communicate in schizophrenia: Functional neuroimaging evidence
	Mary-Claire Hanlon, Australia	Speaker
005	Beyond amygdala: 5-HTTLPR polymorphism and the medial prefrontal cortex
	Cedric Lemogne, France	Speaker
006	Linear and non-linear regional neuroanatomical volume variations due to aging: A voxel-based morphometric MRI study of normal, non-elderly adults
	Pedro Curiati, Brazil	Speaker

No.	SA-06 - Satellite Symposium
Time:	14.00-15.30
Room:	Blue Amphitheatre
Topic:
Session title:	Improving health, cognition and response in schizophrenia supported by an unrestricted educational grant from Lundbeck A/S
	Shitij Kapur, United Kingdom	Chair

001	Strategies for improving cognition in schizophrenia
	Philip D. Harvey, USA	Speaker
002	Long-term health considerations when using antipsychotics
	Marc De Hert, Belgium	Speaker
003	Implications of early response & non-response in schizophrenia
	Shitij Kapur, United Kingdom	Speaker

No.	SA-07 - Satellite Symposium
Time:	14.00-15.30
Room:	Salle Maillot
Topic:	Bipolar Disorders: Basic / Clinical
Session title:	Bipolar Disorder: New Approaches and New Priorities supported by an unrestricted grant from Schering-Plough Corporation.
	Prakash S. Masand, USA	Co-Chair
	Charles-Siegfried Peretti, France	Co-Chair

001	Acute treatment of bipolar disorder
	Prakash S. Masand, USA	Speaker
002	New priorities in the treatment of bipolar disorder: Management of depression
	Roger S. McIntyre, Canada	Speaker
003	Long-term maintenance: Achieving the optimal response
	Eduard Vieta, Spain	Speaker
004	Controversies surrounding bipolar disorder management: Are we all on the same page?
	Mark A. Frye, USA	Speaker

No.	TG-08 - WFSBP Treatment Guidelines
Time:	16.00-17.30
Room:	Room 242A
Topic:	Brain Function
Session title:	Biological markers
	Olya Mikova, Bulgaria	Chair

	Toshikazu Saito, Japan	Presenter
	Peter Riederer, Germany	Presenter

No.	D-08 - Debate
Time:	16.00-17.30
Room:	Room 351
Topic:	Psychopharmacology
Session title:	Are there alternatives to placebo controlled studies for efficacy?
	Stuart Montgomery, United Kingdom	Chair

	Olivier Blin, France	Proponent
	Corrado Barbui, Italy	Opponent

No.	W-11 - Workshop
Time:	16.00-17.30
Room:	Room 242B
Topic:	Psychotic Disorders
Session title:	Pharmacological management of schizophrenia in pregnancy and the puerperium
	Angelika Wieck, United Kingdom	Chair

001	Antipsychotic therapy in pregnancy
	Margareta Reis, Sweden	Speaker
002	Antipsychotic therapy in breast-feeding
	Salvatore Gentile, Italy	Speaker

No.	S-71 - Symposium
Time:	16.00-17.30
Room:	Salle Maillot
Topic:	Neuroimaging
Track:	1 Basic
Session title:	Catatonia: An update
	Pierre Thomas, France	Chair
	David Cohen, France	Co-Chair

001	Introduction
	Pierre Thomas, France	Speaker
002	Child and adolescent catatonia is associated with an increase in mortallity and morbidity: Evidence from a prospective follow-up study
	David Cohen, France	Speaker
003	Catatonic syndrome in liaison psychiatry: An overview
	Olivier Cottencin, France	Speaker
004	Pathophysiology and the orbitofrontal cortex in Catatonia
	Georg Northoff, Germany	Speaker

No.	S-72 - Symposium
Time:	16.00-17.30
Room:	Room 352AB
Topic:	Other
Track:	1 Basic
Session title:	Recent advances of psychoneuroimmunological study of psychiatric disorders
	Brian E. Leonard, Ireland	Chair
	Shigenobu Kanba, Japan	Co-Chair

001	Anti-inflammatory effects of antidepressants: Implications for pathophysiology of depression
	Akira Monji, Japan	Speaker
002	The mild encephalitis-hypothesis - new findings and studies
	Karl Bechter, Germany	Speaker
003	The role of antiinflammatory therapy in psychiatry
	Norbert Müller, Germany	Speaker
004	Stress and immune markers in depression
	Ted Dinan, Ireland	Speaker

No.	S-73 - Symposium
Time:	16.00-17.30
Room:	Room 252B
Topic:	Childhood Adolescent Disorder
Track:	1 Basic
Session title:	Biological child and adolescent psychiatry
	Manfred Gerlach, Germany	Chair
	Johannes Thome, United Kingdom	Co-Chair

001	Neurobiology of child and adolescent ADHD
	Marcel Romanos, Germany	Speaker
002	Proteomic research in autism
	Johannes Thome, United Kingdom	Speaker
003	Genetics of early-onset obsessive compulsive disorders
	Susanne Walitza, Switzerland	Speaker
004	Potential biological markers of early-onset schizophrenia
	Claudia Mehler-Wex, Germany	Speaker

No.	S-74 - Symposium
Time:	16.00-17.30
Room:	Room 241
Topic:	Affective Disorders (Unipolar)
Track:	2 Clinical
Session title:	Chronobiological treatment combinations for major affective disorder: Clinical outcome and neurobiological correlates
	Anna Wirz-Justice, Switzerland	Chair
	Sylvie Royant-Parola, France	Co-Chair

001	Chronobiology as a paradigm for biological psychiatry
	Anna Wirz-Justice, Switzerland	Speaker
002	Nuts and bolts of chronotherapeutic interventions
	Michael Terman, USA	Speaker
003	Wake and light therapy in non-seasonal major depression
	Klaus Martiny, Denmark	Speaker
004	Wake and light therapy in bipolar illness: fMRI correlates of response
	Francesco Benedetti, Italy	Speaker

No.	S-75 - Symposium
Time:	16.00-17.30
Room:	Room 251
Topic:	Genetics
Track:	1 Basic
Session title:	Recent advances in the neurobiology of suicide
	Kees van Heeringen, Belgium	Chair
	Dan Rujescu, Germany	Co-Chair

001	Separating effects of genes and stress on the neurobiology of suicidal behavior
	Leo Sher, USA	Speaker
002	Early life adversity, biological modifications and impulsive-aggressive suicide
	Gustavo Turecki, Canada	Speaker
003	Orbitofrontal cortex, decision-making and suicidal behaviour
	Fabrice Jollant, France	Speaker
004	Genetics of aggressive and impulsive behavior
	Dan Rujescu, Germany	Speaker

No.	SL-03 - Special Lecture
Time:	16.30-17.30
Room:	Blue Amphitheatre
Topic:	Brain Function
Session title:	Brain, mind, society: The threefold cord
	Joseph Zohar, Israel	Chair

001	Brain, mind, society: the threefold cord
	Alain Ehrenberg, France	Speaker

« previous day

Wednesday, 1. July 2009

next day »